Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

ViiV’s two-drug HIV combo backed by CHMP

The committee also backs two biosimilar medicines

Sanofi reception

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

UCB launches online clinical trial tool

Aims to help patients and physicians find its studies

- PMLiVE

A quest for innovative solutions

UCB looks to the future through a PRISM

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

UCB supports social network for SpA patients

MySpondylitisTeam is launched by MyHealthTeams

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links